Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

DES with Bioresorbable Polymer vs. Bare Metal Stents in Primary PCI

Long after myocardial revascularization guidelines had established no medical reason justifies the use of bare metal stents (BMS), along comes this study to refresh the old trials comparing drug eluting vs bare metal stents in the context of primary PCI.

DES con polímero bioabsorbible vs Bare Metal Stents en angioplastia primaria

The problem for many countries is that primary PCI obviously occurs in the context of an emergency and with no time to wait for the insurance company to authorize intervention. In this scenario, it might be complicated for hospitals to get reimbursed for the extra cost of drug eluting stents. In addition, interventional cardiologists aim at getting TIMI 3 flow (that ultimately changes prognosis) and not reintervention, which would eventually become a problem-.

Therefore, conventional stents (BMS) are more commonly used in many countries.

Regardless our reality, we should know what lies ahead and what is best for our patients in the context of primary PCI.


Read also: After Much Toing and Froing, Gastrointestinal Protection Is Back to the Forefront.


This study followed 1157 patients at 5 years (biodegradable polymer-coated biolimus stent n=575 and BMS n=582) included in the randomized trial COMFORTABLE AMI. All serial intracoronary imaging, both intravascular ultrasound (IVUS) and optimal coherence tomography (OCT), were analyzed at baseline and at 13 months.

At 5 years, biodegradable polymer-coated BES reduced major cardiac events (MACE HR: 0.56 CI 95% 0.39 to 0.79; p=0.001). This difference was driven basically by the lower chance of target vessel related infarction (HR 0.44, CI 95%: 0.22 to 0.87, p=0.02) and ischemia driven revascularization (HR 0.41, CI 95%: 0.25 to 0.66, p<0.001). Definite thrombosis was objectivized in 2.2% vs 3.9%, which was only a tendency in favor of DES and there was no difference in very late thrombosis (1.3% vs. 1.6%, p=0.77).

OCT did not show differences in strut malapposition between devices and the uncovered struts were rare, though more frequent with BES. IVUS did not show positive remodeling in either group.

Conclusion

Comparing BMS against biodegradable polymer-coated BES, there was lower MACE rate at 5 years (as regards target vessel MI and new revascularization) in patients undergoing acute myocardial infarction with primary PCI. At 13 months, intravascular imaging showed almost complete scarring with both devices.

Original Title: Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based Biolimus-eluting stents with Bare-metal stents in patients with acute ST-segment elevation myocardial infarction.

Reference: Lorenz Raber et al. European Heart Journal (2019) 0, 1–11. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....